title: beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene.
abstract: In this study, the effects of polymorphisms of the beta(2) and beta(3) adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with beta-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing beta(2)AR Glu27 or the beta(3)AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the beta(2)AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after beta-blockade was four-fold higher in patients homozygous for the beta(2)AR Glu27 variant as compared to beta(2)AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic beta-blockade treatment.
authors: Department of Clinical Medicine, Cardiovascular and Immunological Sciences, School of Medicine Federico II University of Naples, Italy.
authors: G
authors: G
authors: Iaccarino
authors: V
authors: V
authors: Trimarco
authors: F
authors: F
authors: Lanni
authors: E
authors: E
authors: Cipolletta
authors: R
authors: R
authors: Izzo
authors: O
authors: O
authors: Arcucci
authors: N
authors: N
authors: De Luca
authors: G
authors: G
authors: Di Renzo
mesh_terms: D058672:Adrenergic beta-2 Receptor Antagonists; D058673:Adrenergic beta-3 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000483:Alleles; D000959:Antihypertensive Agents / Q000009:adverse effects; D001120:Arginine / Q000235:genetics; D001262:Atenolol / Q000009:adverse effects; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D018698:Glutamic Acid / Q000235:genetics; D006720:Homozygote; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000235:genetics*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008790:Metoprolol / Q000009:adverse effects; D011110:Polymorphism, Genetic; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics* / Q000378:metabolism; D022702:Receptors, Adrenergic, beta-3 / Q000235:genetics / Q000378:metabolism; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D058672:Adrenergic beta-2 Receptor Antagonists; D058673:Adrenergic beta-3 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001786:Blood Glucose; D018343:Receptors, Adrenergic, beta-2; D022702:Receptors, Adrenergic, beta-3; D014280:Triglycerides; D018698:Glutamic Acid; D001262:Atenolol; D001120:Arginine; D002784:Cholesterol; D008790:Metoprolol